Christopher Rhodes

Mimio Health is a nutraceutical company pioneering the world's first fasting mimetic supplement designed from clinical research to replicate the cellular health benefits of fasting without the need to fast. Through years of research into human fasting we have uncovered a conserved metabolic program for cellular health and regeneration that underpins the beneficial effects of fasting. Our patent-pending fasting mimetic formulation uses a rigorously selected combination of the same bioactive human metabolites that induce this regenerative "bio-program" to replicate the body’s natural response to fasting without having to fast. We have shown that our fasting mimetic is capable of extending the lifespan of model organisms by 96% and can replicate the same anti-inflammatory, antioxidant, and cardioprotective effects of fasting in pilot clinical studies. These powerful effects could combat dietary and age-associated chronic inflammation and cellular damage allowing our customers to live longer, healthier lives.

-Running -omic based compound discovery pipelines for the identification of fasting mimetics -Designing and executing clinical trials of early stage fasting mimetics -Performing primary cell culture based in vitro analyses of the immunological effects of fasting mimetic candidates

Studying the relationship between nutrition and aging with a specific focus on the characterization and quantification of the biochemical mechanisms and effects involved in nutrient restriction (Caloric Restriction/Fasting) and their relationship to extending human healthspan and lifespan. Project: Characterization of the effects of Alternate Day Fasting and other nutritional interventions on numerous aspects of human health: -HDL composition and function -Proteomics, Lipidomics, Glycomics -Serum IgG glycosylation -Microbiome

Conducted immunology research to elucidate the importance of citrullination and netosis in the disease progression of rheumatoid arthritis.